The medical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant potential in clinical trials for treating obesity. Unlike some available weight loss approaches, retatrutide appears to provide a greater substantial reduction in body mass and enhance metabolic health,